Because high plasma concentrations of homocysteine constitute an enhanced risk for premature coronary heart disease, it is necessary to establish a reference range for normal concentrations of plasma homocysteine. The frequency distribution of plasma homocysteine concentrations tails to the right, and the nonparametric approach is unsatisfactory for defining a normal plasma homocysteine reference range. By using subjects' responses to appropriate vitamin supplementation, we developed a mathematical prediction model to calculate the plasma homocysteine concentration that could be expected for each individual treated with a vitamin supplement. With this model, we can predict that plasma homocysteine concentrations will approach a normal frequency distribution with a 95% reference range (mean ± 2 SD) of 4.9-11.7 moI/L, provided the vitamin status of the study population is improved. 
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Because high plasma concentrations of homocysteine constitute an enhanced risk for premature coronary heart disease, it is necessary to establish a reference range for normal concentrations of plasma homocysteine. The frequency distribution of plasma homocysteine concentrations tails to the right, and the nonparametric approach is unsatisfactory for defining a normal plasma homocysteine reference range. By using subjects' responses to appropriate vitamin supplementation, we developed a mathematical prediction model to calculate the plasma homocysteine concentration that could be expected for each individual treated with a vitamin supplement. With this model, we can predict that plasma homocysteine concentrations will approach a normal frequency distribution with a 95% reference range (mean ± 2 SD) of 4.9-11.7 moI/L, provided the vitamin status of the study population is improved.
Indexing Terms: coronaty heart disease/nutritional status/risk factors/folate/vitamin B,2
Coronary heart disease (CHD) is a multifactorial condition that is one of the primary causes of premature death in Western societies. Aithough established risk factors for CHD, such as an above-normal concentration of low-density lipoprotein cholesterol in serum, hypertension, and smoking, have been studied exhaustively, these factors explain only -50% of all CHD cases (1). Obviously, other risk factors are also involved in the etiology of atherosclerosis and CHD. Hyperhomocysteinemia may be an additional risk factor predisposing individuals to premature CHD. Patients homozygous for cystathionine-(3-synthase deficiency, or who have inherited disorders of cobalamin metabolism (e.g., Cbl C syndrome), have very high plasma homocysteine concentrations and are usually subject to severe, premature atherosclerosis (2, 3) . Recently, laboratory techniques to measure plasma homocysteine concentrations have become more readily available (4-6), and the observations made in cystathionine-3-synthase-deficient patients have been extended to the general population, where milder forms of hyperhomocysteinemia may be common (7) (8) (9) . Cir 
Materials and Methods

High-CHD-Risk Population and Homocysteine Assay
Since July 1991 we have measured plasma homocysteine concentrations in 1437 adult white men, ages 18-65 years. All apparently healthy and employed by major employers in the Pretoria area, they adhered to a typical Western life-style. The prevalence of CHD in this group is among the highest in the world (32) .
Venous blood samples with EDTA as anticoagulant were obtained for homocysteine analyses; the blood samples were chilled on ice and plasma was separated from blood cells within 1 h. Plasma homocysteine concentrations were determined by HPLC according to a modification of the method of Araki and Sako (5, 6 ). This method entails complete reduction of homocystine and the mixed disulfide (cysteine-homocysteine), and the release of protein-bound homocysteine. The method therefore measures total (free + protein-bound) plasma homocysteine concentrations.
Vitamin Supplementation Study
From the group of 1437 men, 72 who had relatively high (>1.3 molJL) plasma homocysteine concentrations and did not use vitamin supplements participated in three clinical trials to study the effect of vitamin supplementation on circulating homocysteine concentrations.
Full details of these trials have been published (7, 33, 34) and the results are summarized in Table 1 .
In each study, different vitamin supplements (Table  1) were used to lower the plasma homocysteine concentrations over a 6-week period. Plasma homocysteine concentrations were measured at the start of each study and after 6 weeks of vitamin supplementation. The vitamin concentrations in plasma were monitored after 3 and 6 weeks to assess compliance.
These trials, however, provided information only on the effect of vitamin therapy on plasma homocysteine concentrations >16.3 moWL. To establish the effect of vitamin supplementation on lower plasma homocysteine concentrations, we studied 19 white men [mean (SD) age: 20 (1.0) years] who did not consume vitamin supplements before the study and who had relatively low plasma homocysteine concentrations (<16.3 moV L). They were supplied with a vitamin combination (1.0 mg of folic acid, 0.4 mg of vitamin B,2, 10 mg of pyridoxine) and were requested to take one tablet per day for 6 weeks. Plasma homocysteine concentrations were measured at the start of the study and again after the 6-week supplementation period. Plasma vitamin concentrations were monitored as indicated above to assess compliance.
Mathematical Model for Estimating Probable Effect of Vitamin Supplementation on Plasma Homocysteine
In all, data from 91 subjects who had been treated for 6 weeks with various vitamin supplements were available to determine the relationship between plasma homocysteine concentrations before and after vitamin supplementation.
Although different supplements were used in separate trials (Table 1) , we were able to combine the data for the following reasons:
1. The designs of the trials were similar; each studied the effect of the vitamin supplement on plasma homocysteine concentrations for 6 weeks. 2. The various vitamin supplements used were equally effective and did not differ significantly in their respective effects on plasma homocysteine concentrations. For example, supplementation with a vitamin combination (folic acid, vitamin B,2, and pyridoxine) did not differ significantly from folic acid supplementation alone with respect to lowering plasma homocysteine concentrations (34) . The data from the 91 vitamin-treated subjects were carefully screened, and those from 16 subjects were omitted from further data analyses. Excluded subjects either had an unsatisfactory compliance record according to blood vitamin analyses (n = 6), or were severely vitamin B,2 deficient and did not respond to oral vitamin supplementation (n = 4). Six individuals who had basal plasma homocysteine concentrations >50
mo1fL
were also excluded; the number of those data points was considered too few to allow accurate estimation of the general effect of vitamin supplementation on plasma homocysteine concentrations >50 mol/L, and we wanted not to bias the response to vitamin supple- 
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[Wilk-Shapiro test statistic (37, 38) for normality = 0.64 (Fig. 2) ].
We reported previously that a high plasma homocysteune concentration is significantly reduced after vitamiii supplementation (7,33, 34) . In the present study, we found that treating a young adult population with a mean (SD) plasma homocysteine concentration of 10.0 (3.7) moI/L with a vitamin combination also reduced the mean plasma homocysteine concentration significantly (P <0.001, Student's paired t-test), to 7.3 (1.6) umol/L. Therefore, we combined these data with the previously reported results obtained on vitamintreated subjects with higher plasma homocysteine concentrations ( Table 1) and fitted a piecewise linear regression line to the combined sets of data to describe the relation between the ratio of post-to pre-and the pretreatment plasma homocysteine concentrations. The regression line is described by the equation The adjusted frequency distribution refers to the expected distribution In these subjects after appropriate vitamin supplementation.
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Basal Homocysteine concentration (pmol/L) Fig. 1 . Scatter plot of pretreatment plasma homocysteine concentrations vs the ratio of post-and pretreatment plasma homocysteine concentrations.
Data were derived from the studies quoted In Table 1 . The piecewise linear regression line was fitted to the data by using the method of least squares. The circled data points were outliers and were omitted when the piecewise linear regression line was fitted to the data (see text).
mentation by the few patients with very high basal plasma homocysteine values. Using data from the remaining subjects (n = 75), we constructed a scatter plot of pretreatment plasma homocysteine concentrations vs the ratio of post-and pretreatment plasma homocysteine concentrations. Then, by the method of least squares, a piecewise linear regression (35) line with one node at a pretreatment homocysteine concentration of 26 moI/L was fitted to the data (Fig. 1) . The node at 26 mo1/L corresponds to the piecewise linear regression line with the least mean square error. The general notation of the piecewise linear regression model is: Fig. 1 . The piecewise linear regression line was eventually fitted to 71 data points, and the regression equation was used to calculate the estimated plasma homocysteine concentration for each individual in the total population group, as if he had been treated with a suitable vitamin formulation for 6 weeks.
Results
The mean (SD) plasma homocysteine concentration of the study population was 12.0(6.7) molfL (Table 2 ), but the frequency distribution was positively skewed is 72.2%. Therefore, 72.2% of the variation in the plasma homocysteine concentration ratio described above can be explained by the variation in pretreatment plasma homocysteine concentrations.
Using the above-mentioned equation, we calculated the plasma homocysteine concentration that
The mean (SD) adjusted homocysteine concentration was 8.3 (1.7) p.mol/L, and the frequency distribution was normal ( Fig. 2 ; Wilk-Shapiro test statistic for normality = 0.99).
Discussion
The skew (tailed) frequency distribution of plasma homocysteine concentrations in the studied population group may be typical of CHD-prone Western populations and has been reported previously (7, 19,21) . According to the Physicians Health Study, the risk for myocardial infarction increased 3.4-fold in cases with plasma homocysteine concentrations in the tailed part of the homocysteine frequency distribution curve (19) . It may therefore be inappropriate to include the tail of the plasma homocysteine distribution curve in a definition of plasma homocysteine concentrations associated with good health. Therefore, even the nonparametric determination of 95% normal limits will be unsuitable to define a reference range for plasma homocysteine.
According to the nonparametric approach, the 97.5th percentile represents the upper normal limit of the variable. In our study, the 97.5th percentile corresponds to a plasma homocysteine concentration of 30.1 .tmoIIL, and the 95% reference range will still include a substantial proportion of the tail of the frequency distribution.
Because the nonparametric approach is unsatisfactory, we used a mathematical prediction model to calculate a possibly more appropriate plasma homocysteine reference range. Using the regression equation that describes the relation between pre-and postvitamiii supplementation homocysteine concentrations, we calculated the effect that vitamin therapy could be expected to have on each individual (with plasma homocysteine <50 molIL) from the study population. The results show that vitamin therapy would probably reduce the mean (SD) plasma homocysteine concentration from 12.0 (6.7) to 8.3 (1.7) moI/L. Furthermore, the distribution of adjusted plasma homocysteine concentrations is gaussian (Fig. 2) , implying that the plasma homocysteine reference range will then be 4.9-11.7 moI/L (mean ± 2 SD). This calculated upper normal limit is considerably lower than the nonparametrically defined upper normal limit. Our mathematical model and calculated reference range are based on nutritional considerations, given that an adequate vitamin status was obtained in a relatively small study population through vitamin supplementation.
The proposed reference range was then derived by extrapolation from the change in plasma homocysteine concentrations in the vitamin-supplemented individuals to the general population.
It CHD is conferred to the patient. Such studies will be essential for evaluating the normal reference range for plasma homocysteine as predicted by our model. Furthermore, epidemiological studies on population groups with a low CHD incidence will also be useful to gain a better perspective on the preferred plasma homocysteine concentration range. Finally, it may also be possible to refine the model by taking into account other factors (i.e., age) that might influence plasma homocysteine concentrations, and women may require a separate reference range.
In summary, our results indicate that the plasma homocysteine frequency distribution in a CHD-prone population tails to the right, but mathematical modelling suggests that the tail of the frequency distribution reflects an inadequate vitamin status, which will disappear when the general vitamin status is improved. Based on the mathematical prediction model, a plasma homocysteine reference range between 4.9 and 11.7 mo1/L is suggested. This study again emphasizes that a substantial proportion of an affluent society may have high plasma homocysteune concentrations due to an imprudent diet, which may put them at increased risk for premature vascular disease. Because hyperhomocysteinemia may be easily corrected by simple dietary measures, it seems appropriate to screen for, and treat, this disorder on a routine basis.
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